Literature DB >> 27056923

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Olivier Kosmider1, Marie Passet1, Valeria Santini2, Uwe Platzbecker3, Valérie Andrieu4, Gina Zini5, Odile Beyne-Rauzy6, Agnès Guerci7, Erico Masala8, Enrico Balleari9, Ekaterina Bulycheva3, François Dreyfus10, Pierre Fenaux11, Michaela Fontenay1, Sophie Park12.   

Abstract

Entities:  

Keywords:  cytogenetics and molecular genetics; myelodysplastic syndromes; red cells

Mesh：

Substances：

Year:  2016        PMID： 27056923      PMCID： PMC5004472          DOI： 10.3324/haematol.2016.142695

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Authors:  Valeria Santini; Jennifer Schemenau; Alessandro Levis; Enrico Balleari; Rosa Sapena; Lionel Adès; Agnès Guerci; Odile Beyne-Rauzy; Marie-Pierre Gourin; Stephane Cheze; Aspasia Stamatoullas; Alessandro Sanna; Daniela Gioia; Gianni Cametti; Dario Ferrero; Emmanuel Raffoux; Christian Rose; Antonella Poloni; Thomas Prebet; Laurence Legros; Shanti Natarajan-Amé; Pierre Fenaux; Ulrich Germing; François Dreyfus; Sophie Park
Journal:  Blood       Date:  2013-09-26       Impact factor: 22.113

2.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Authors:  Peter L Greenberg; Zhuoxin Sun; Kenneth B Miller; John M Bennett; Martin S Tallman; Gordon Dewald; Elisabeth Paietta; Richard van der Jagt; Jessie Houston; Mary L Thomas; David Cella; Jacob M Rowe
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

3.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

Authors:  Eva Hellström-Lindberg; Nina Gulbrandsen; Greger Lindberg; Tomas Ahlgren; Inger Marie S Dahl; Ingunn Dybedal; Gunnar Grimfors; Eva Hesse-Sundin; Martin Hjorth; Lena Kanter-Lewensohn; Olle Linder; Michaela Luthman; Eva Löfvenberg; Gunnar Oberg; Anja Porwit-MacDonald; Anders Rådlund; Jan Samuelsson; Jon Magnus Tangen; Ingemar Winquist; Finn Wisloff
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

4.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

6.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Authors:  Sophie Park; Sophie Grabar; Charikleia Kelaidi; Odile Beyne-Rauzy; Françoise Picard; Valérie Bardet; Valérie Coiteux; Geneviève Leroux; Pascale Lepelley; Marie-Thérèse Daniel; Stéphane Cheze; Béatrice Mahé; Augustin Ferrant; Christophe Ravoet; Martine Escoffre-Barbe; Lionel Adès; Norbert Vey; Lina Aljassem; Aspasia Stamatoullas; Lionel Mannone; Hervé Dombret; Keith Bourgeois; Peter Greenberg; Pierre Fenaux; François Dreyfus
Journal:  Blood       Date:  2007-10-16       Impact factor: 22.113

7.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett A Caughey; Omar Abdel-Wahab; David P Steensma; Naomi Galili; Azra Raza; Hagop Kantarjian; Ross L Levine; Donna Neuberg; Guillermo Garcia-Manero; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

8.  Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.

Authors:  Theresia M Westers; Canan Alhan; Martine E D Chamuleau; Maurice J D L van der Vorst; Corien Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Blood       Date:  2009-12-28       Impact factor: 22.113

9.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

10.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528
View more
  8 in total

1.  Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Authors:  Felicitas Thol; Uwe Platzbecker
Journal:  Blood Adv       Date:  2019-11-12

2.  Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Authors:  Guillermo F Sanz; Mariam Ibañez; Esperanza Such
Journal:  Blood Adv       Date:  2019-11-12

Review 3.  Treatment of low-risk myelodysplastic syndromes.

Authors:  Valeria Santini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.

Authors:  M Teresa Cedena; Inmaculada Rapado; Alejandro Santos-Lozano; Rosa Ayala; Esther Onecha; María Abaigar; Esperanza Such; Fernando Ramos; José Cervera; María Díez-Campelo; Guillermo Sanz; Jesús Hernández Rivas; Alejandro Lucía; Joaquin Martínez-López
Journal:  Oncotarget       Date:  2017-10-27

5.  Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes.

Authors:  Mathieu Meunier; Charles Dussiau; Natacha Mauz; Anne Sophie Alary; Christine Lefebvre; Gautier Szymanski; Mylène Pezet; Françoise Blanquet; Olivier Kosmider; Sophie Park
Journal:  Oncotarget       Date:  2018-02-20

Review 6.  Treatment options for lower-risk myelodysplastic syndromes. Where are we now?

Authors:  Virginia O Volpe; Rami S Komrokji
Journal:  Ther Adv Hematol       Date:  2021-01-14

7.  Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Authors:  Sophie Park; Olivier Kosmider; Frédéric Maloisel; Bernard Drenou; Nicolas Chapuis; Thibaud Lefebvre; Zoubida Karim; Hervé Puy; Anne Sophie Alary; Sarah Ducamp; Frédérique Verdier; Cécile Bouilloux; Alice Rousseau; Marie-Christine Jacob; Agathe Debliquis; Agnes Charpentier; Emmanuel Gyan; Bruno Anglaret; Cecile Leyronnas; Selim Corm; Borhane Slama; Stephane Cheze; Kamel Laribi; Shanti Amé; Christian Rose; Florence Lachenal; Andrea Toma; Gian Matteo Pica; Martin Carre; Frédéric Garban; Clara Mariette; Jean-Yves Cahn; Mathieu Meunier; Olivier Herault; Pierre Fenaux; Orianne Wagner-Ballon; Valerie Bardet; Francois Dreyfus; Michaela Fontenay
Journal:  Haematologica       Date:  2018-10-04       Impact factor: 9.941

Review 8.  Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.

Authors:  Ulrich Germing; Ester N Oliva; Devendra Hiwase; Antonio Almeida
Journal:  Hemasphere       Date:  2019-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.